Last updated: March 1, 2026
What Is NDC 70954-0157?
NDC 70954-0157 refers to a specific pharmaceutical product registered with the FDA. According to available data, this NDC corresponds to Rituximab, a monoclonal antibody used primarily for non-Hodgkin's lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, and other autoimmune conditions. The drug is marketed by multiple manufacturers, including Roche and generic manufacturers.
Market Size and Demand Drivers
Therapeutic Area Demand
Rituximab is a blockbuster drug with annual global sales exceeding USD 7 billion. Primary markets include:
- United States: 65-70% of global sales
- Europe: 20-25%
- Rest of world: 10-15%
Treatment Indications and Growth
Key indications include:
- Non-Hodgkin's lymphoma (NHL)
- Chronic lymphocytic leukemia (CLL)
- Rheumatoid arthritis (RA)
- Granulomatosis with polyangiitis
Market growth stems from expanding approved indications and increasing adoption in biosimilars.
Biosimilar Competition
Since 2017, biosimilar versions have entered major markets. For Rituximab, biosimilar products have gained approval or are under development in several regions, including:
- Europe: Multiple biosimilars approved since 2017 (e.g., Celltrion's Truxima, Sandoz's Ruxience)
- U.S.: First biosimilars launched in 2019 (e.g., Pfizer's Ruxience, Sandoz's Ruxience, and Celltrion's Truxima)
Market share shifts favor biosimilars, pressuring innovator pricing.
Current Pricing Landscape
Brand-Name Rituximab
In the U.S., list prices (Wholesale Acquisition Cost, WAC) for the innovator brand are approximately USD 4,700 per 100 mg vial and USD 8,200 per 500 mg vial (as of 2023). The average treatment course costs USD 30,000–USD 50,000.
Biosimilar Pricing
Biosimilars entered the U.S. market with prices roughly 15%-30% lower than the branded product initial launch. Current average sale prices for biosimilars range between USD 3,000–USD 6,000 per 100 mg vial. Biosimilar uptake varies by region but generally increases, leading to downward pricing pressure.
Contract and Discounting Trends
Hospitals and pharmacy benefit managers negotiate significant discounts, with net prices often 40%-60% below list prices.
Price Projections
Short-term (Next 1-2 Years)
- The biosimilar market share is expected to increase by 10-20% annually.
- List prices are likely to remain stable or decrease slightly (2%-5%) due to biosimilar competition.
- Net prices could decline by 10% as hospitals and payers leverage biosimilar discounts.
Mid-term (Next 3-5 Years)
- Biosimilar penetration could reach 50% globally, depending on regional regulatory policies.
- List prices may decrease further, driven by increased biosimilar supply and payer pressure.
- Price for the branded Rituximab could fall 15%-20% in key markets.
Long-term (Beyond 5 Years)
- Biosimilar market share could constitute over 70%, pushing average prices down by 35%-50%.
- Patent litigations and exclusivity periods will influence timing and extent of price declines.
- New formulations or indications may impact market dynamics, either stabilizing or reducing prices.
Region-Specific Considerations
| Region |
Expected Biosimilar Adoption |
Price Trend |
Key Factors |
| U.S. |
High |
15-25% decrease over 3-5 years |
Patent expirations, regulatory approval of biosimilars, payer policies |
| Europe |
Very high |
20-30% decrease over 2-4 years |
Established biosimilar market, price regulation policies |
| Asia |
Moderate |
10-20% decrease over 4-6 years |
Market expansion, regulatory environments evolving |
Competitive Positioning
The market will continue to be influenced by:
- Patent status and litigation outcomes.
- Biosimilar acceptance by clinicians and payers.
- Pricing strategies by originator and biosimilar companies.
- Regulatory policies affecting interchangeability and substitution.
Key Takeaways
- The innovator Rituximab remains a high-value product with global sales exceeding USD 7 billion.
- Biosimilar counterparts introduce persistent price competition, reducing net prices by 40-60% over time.
- Short-term price declines are modest, but by 5 years, prices could fall by up to 50%.
- Regional market dynamics differ, with the U.S. and Europe adopting biosimilars more rapidly than other regions.
- Pricing strategies will adapt to biosimilar penetration, patent cliffs, and regulatory shifts.
FAQs
1. What is the primary driver of Rituximab price reduction?
Biosimilar competition, especially in regions with established approval pathways, drives prices downward.
2. How does patent expiration affect market prices?
Expiration allows biosimilar entry, increasing competition and leading to significant price reductions.
3. Are biosimilars approved for all indications of the original drug?
Not always; some approvals are based on extrapolation, but initial uptake depends on specific licensing.
4. How do regional policies influence Rituximab pricing?
Regions with strict price controls or active biosimilar policies tend to see faster and larger price decreases.
5. Will the demand for Rituximab decline due to biosimilars?
Overall demand remains stable or increases, but market share shifts towards biosimilars, affecting price and revenue.
References
[1] IQVIA. (2023). Global Oncology Market Report.
[2] U.S. Food and Drug Administration. (2022). Biologics Price Competition and Innovation Act.
[3] EvaluatePharma. (2023). World Market Outlook for Monoclonal Antibodies.
[4] Sandoz. (2022). Biosimilar Rituximab Launch Details.
[5] European Medicines Agency. (2021). Rituximab Biosimilars Approvals and Guidelines.
